Every Form 4 that Ekso Bionics Holdings, Inc. (EKSO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EKSO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EKSO filings page.
Cummins Wes reported acquisition or exercise transactions in this Form 4 filing.
ChronoScale Corp director Wes Cummins received a grant of 200,000 restricted shares of common stock as equity compensation. The grant was made on May 14, 2026 and all shares are held directly, bringing his reported direct common stock holdings to 200,000 shares.
According to the vesting schedule, 100,000 restricted shares will vest on the one-year anniversary of the grant date and the remaining 100,000 will vest on the two-year anniversary, conditioned on his continuous service with the company and subject to possible adjustment or accelerated vesting upon certain conditions.
Nottenburg Richard N reported acquisition or exercise transactions in this Form 4 filing.
ChronoScale Corp reported that director Richard N. Nottenburg received a grant of 200,000 shares of restricted common stock on May 14, 2026. These shares were awarded at $0.00 per share as equity compensation, not as an open‑market purchase.
According to the vesting schedule, 100,000 restricted shares will vest on the first anniversary of the grant date and another 100,000 restricted shares will vest on the second anniversary. Vesting is conditioned on his continuous service with ChronoScale and may be adjusted or accelerated under certain conditions. After this grant, he directly holds 200,000 ChronoScale shares.
ChronoScale Corp Chief Financial Officer Jerome Wong reported new equity compensation and updated holdings. He received 40,000 shares of common stock at a price of $0.00 per share as a grant or award acquisition tied to performance-based restricted stock units under the company’s Amended and Restated 2014 Equity Incentive Plan. Following this award, he directly holds 64,771 shares of common stock and indirectly holds 4,184 shares through a 401(k) account.
MILLER DOUGLAS S reported acquisition or exercise transactions in this Form 4 filing.
ChronoScale Corp director Douglas S. Miller received a grant of 200,000 restricted shares of common stock as equity compensation. The award was granted on May 14, 2026 at no purchase price. According to the terms, 100,000 restricted shares vest on the one-year anniversary of the grant date and 100,000 vest on the two-year anniversary.
Each vesting tranche requires Miller to remain in continuous service with ChronoScale through the applicable vesting date, and the award may be adjusted or vest earlier under certain specified conditions. After this grant, Miller holds 200,000 shares directly.
Ekso Bionics Holdings Chief Operating Officer Jason C. Jones increased his ownership through a small share acquisition tied to the company’s retirement plan. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share in an open-market purchase recorded under his 401(k) account, as part of the issuer’s 401(k) contribution matching program.
After this transaction, he indirectly holds 4,449 shares through the 401(k) and directly holds 25,621 shares of common stock. The share amounts disclosed have been adjusted to reflect a prior 1-for-15 reverse stock split.
Ekso Bionics Holdings, Inc. Chief Financial Officer Jerome Wong reported an open-market purchase of common stock through a 401(k) plan. He acquired 1,308 shares on March 16, 2026 at $11.85 per share, held indirectly via a 401(k) account under the company’s matching contribution program.
Following this transaction, he indirectly held 4,184 shares through the 401(k) and directly held 24,771 shares of common stock. A prior 1-for-15 reverse stock split effective on June 2, 2025 is reflected in the reported share amounts.
Ekso Bionics Holdings, Inc. insider Daniel Asher, a more than ten percent owner, reported an indirect open-market purchase of common stock. On February 19, 2026, DBA Trading, LLC, an entity beneficially owned by Asher, bought 15,540 shares of common stock at an average price of $12.3013 per share. After this trade, DBA Trading, LLC held 270,432 common shares indirectly for Asher. Asher is also shown as indirectly holding 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, and directly holding 165,000 common shares, reflecting a significant overall stake in Ekso Bionics.
Ekso Bionics Holdings insider activity centers on an indirect open-market purchase and updated holdings. An entity associated with major shareholder Daniel Asher, DBA Trading, LLC, bought 1,200 shares of common stock at $9.60 per share, increasing its indirect position to 259,992 common shares. Asher is described as the beneficial owner of DBA Trading, LLC with voting and dispositive control over these shares.
The filing also reports indirect holdings of 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, where Asher is grantor and controls voting and dispositive power, and 165,000 common shares held directly. The preferred and direct common entries are reported as holdings rather than new transactions.
Ekso Bionics Holdings, Inc. major shareholder Daniel Asher reported a series of indirect open-market purchases of common stock through DBA Trading, LLC between February 6 and February 13, 2026, at prices around the high-$8 to mid-$9 range per share.
Following these trades, DBA Trading, LLC held 258,792 shares of Ekso Bionics common stock indirectly for Asher, while he also reported 165,000 shares of common stock held directly. In addition, a trust for which Asher is grantor held 2,926 shares of convertible preferred stock, convertible into 355,960 shares of common stock, all reported as indirect beneficial ownership.
Ekso Bionics Holdings, Inc. Chief Operating Officer Jason C. Jones reported a sale of company stock in a Form 4 filing. On January 6, 2026, he sold 1,320 shares of common stock at $9.25 per share, with the filing explaining that the sale was made to cover tax withholding obligations from the vesting and settlement of restricted stock awards.
After this transaction, Jones beneficially owned 25,621 shares of Ekso Bionics common stock directly and 3,141 shares indirectly through a 401(k) plan. The filing notes that these share amounts have been adjusted to reflect a 1-for-15 reverse stock split that took effect on June 2, 2025.
Ekso Bionics (EKSO) disclosed a Form 4 for CFO Jerome Wong. He sold 11,288 shares of common stock on November 10, 2025 at $4.799 per share to cover tax withholding upon the vesting and settlement of restricted stock awards.
After the transaction, Wong beneficially owns 26,009 shares directly and 2,876 shares indirectly via a 401(k). Share amounts reflect the issuer’s 1‑for‑15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider transaction by its Chief Operating Officer. On 11/10/2025, the executive sold 9,723 shares of common stock in a single transaction at $4.7990 per share. The filing states the sale was made to cover tax withholding obligations arising from the vesting and settlement of previously reported restricted stock awards.
Following the sale, the reporting person beneficially owns 27,211 shares directly and 3,141 shares indirectly through a 401(k). The company effected a 1‑for‑15 reverse stock split on June 2, 2025, and the reported amounts reflect that adjustment.
Ekso Bionics Holdings (EKSO) reported an insider transaction on Form 4. The reporting person, who serves as CEO and director, sold 23,315 shares of common stock on November 10, 2025 at $4.7990 per share. The filing states the sale was to cover tax withholding obligations arising from the vesting and settlement of restricted stock awards.
After the transaction, the reporting person beneficially owned 78,777 shares directly and 373 shares indirectly through a 401(k). The company previously effected a 1-for-15 reverse stock split on June 2, 2025, and the amounts in the filing reflect that adjustment.
Ekso Bionics Holdings (EKSO) disclosed an insider equity grant on Form 4. On 11/05/2025, the reporting person, a Director and CEO, received 80,000 restricted stock units (RSUs) at a price of $0, granted under the Amended and Restated 2014 Equity Incentive Plan. The award was fully vested at grant and settles in shares upon vesting. Following the transaction, the insider beneficially owned 102,092 shares directly and 373 shares via a 401(k). The company effected a 1-for-15 reverse stock split on 06/02/2025, and reported amounts reflect this adjustment.
Ekso Bionics Holdings (EKSO) reported an insider equity grant on Form 4. On November 5, 2025, the Chief Operating Officer received 15,000 restricted stock units (RSUs) at a stated price of $0. The filing states the award was fully vested at grant under the company’s Amended and Restated 2014 Equity Incentive Plan.
Following the transaction, the reporting person beneficially owns 36,934 shares directly and 3,141 shares indirectly via a 401(k). Share amounts reflect the 1-for-15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider equity award for its Chief Financial Officer. On 11/05/2025, the officer acquired 19,500 restricted stock units (RSUs) at $0 under the Amended and Restated 2014 Equity Incentive Plan. The filing states each RSU equals one share and the award was fully vested at grant.
Following the transaction, the officer beneficially owned 37,297 shares directly and 2,876 shares indirectly via a 401(k). The company previously implemented a 1-for-15 reverse stock split on June 2, 2025, and amounts reflect that adjustment.